ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 95

IL-21-mediated Suppression of STAT5 Phosphorylation Underlies Treg Depletion and Dysfunction in SLE

Hiroshi Kato1 and Andras Perl 1, 1SUNY Upstate Medical University, Syracuse, NY

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: cytokines and transcription factor, Systemic lupus erythematosus (SLE), T-Regulatory Cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: IL-21 activates mechanistic target of rapamycin (mTOR) complexes 1 and 2 which in turn block regulatory T (Treg)-cell differentiation and function in patients with SLE. While both IL-21 and IL-6 phosphorylate STAT3 in CD4+ T cells cultured under Treg-polarizing conditions, only IL-21 stimulates mTOR and abrogates Treg-cell differentiation in humans (Arthritis Rheumatol. 2018 Mar;70(3):427-438). This suggests that IL-21 blocks Treg-cell differentiation through an mTOR-dependent, but STAT3-independent mechanism. However, it remains unclear how IL-21-driven mTOR activation elicits Treg-cell depletion and dysfunction in SLE.

Methods: Naïve CD4+ T cells from 9 pairs of matched SLE and healthy control (HC) subjects were cultured for 24 hours in the presence of anti-CD3/CD28, TGF-β (5 ng/ml), and IL-2 (50 IU/ml) (hereafter designated Treg-polarizing conditions) with or without IL-21 (10 ng/ml). As a control, CD4+ T cells from 3 matched SLE and HC subjects were cultured for 72 hours in the presence of anti-CD3/CD28 and TGF-β (20 ng/ml) with or without IL-2 (100 IU/ml). Expression and phosphorylation of STAT5 at tyrosine 694 were detected by immunoblotting. The signal intensity of phospho-STAT5 was normalized to that of actin. Statistical significance was determined by a two-tailed t-test using GraphPad Prism version 5 software.

Results: IL-2 induced the phosphorylation of STAT5 in CD4+ T cells from patients with SLE (p< 0.005). Conversely, IL-21 suppressed STAT5 phosphorylation in naïve CD4+ T cells cultured under Treg-polarizing conditions both in HC and SLE subjects (p< 0.05). Following 24 hours of Treg polarization, CD4+ T cells from SLE patients exhibited diminished STAT5 phosphorylation as compared with those from HC subjects (p< 0.05).

Conclusion: In light of the essential roles for STAT5 in Treg-cell differentiation, our data suggests that IL-21-mediated suppression of STAT5 phosphorylation underlies the Treg-cell depletion and dysfunction in patients with SLE.


Disclosure: H. Kato, None; A. Perl, None.

To cite this abstract in AMA style:

Kato H, Perl A. IL-21-mediated Suppression of STAT5 Phosphorylation Underlies Treg Depletion and Dysfunction in SLE [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/il-21-mediated-suppression-of-stat5-phosphorylation-underlies-treg-depletion-and-dysfunction-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-21-mediated-suppression-of-stat5-phosphorylation-underlies-treg-depletion-and-dysfunction-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology